Table of Contents
EU-GMP cannabis plants do not look or behave like upgraded US grows. They run much closer to compact pharmaceutical factories, where the building, the people, and the software all exist to prove that every batch is safe, consistent, and fit for medical or clinical use. For North American operators and vendors, these facilities are a preview of what “global-grade” production actually entails.
What EU-GMP really means for cannabis
In Europe, EU-GMP is not a marketing label; it is the same standard conventional drug manufacturers follow, and it is a hard requirement for serious medical and pharmacy channels. Instead of focusing on cameras, diversion control, or seed‑to‑sale tags, regulators and Qualified Persons (QPs) care about whether processes are defined, validated, and routinely proven to be under control.
That shift changes the questions that matter inside the plant. It is no longer “Can we show the inspector where the product is?” as much as “Can we prove this process works, and can we show what we did when something went wrong?” Process validation, stability data, and batch documentation all become core operational outputs, not side projects for the QA team.
SOMAÍ: designing a manufacturing hub, not a grow with a lab
SOMAÍ Pharmaceuticals’ Lisbon facility is a good starting point because it was designed for EU-GMP from day one, not retrofitted after the fact. The company built a roughly 3,800 m² extraction and manufacturing site in Portugal, structured across manufacturing floors, in‑house QC labs, and office space that are clearly separated and controlled instead of being wedged into a generic warehouse footprint.
Earning EU-GMP certification from Infarmed meant demonstrating control over premises, utilities, and equipment as well as documentation and quality systems. That includes validated production processes, a functioning CAPA system, and quality control that can withstand scrutiny from both domestic regulators and authorities in key export markets like Germany and the UK. For SOMAÍ, the “export-ready” positioning is not just about price or potency; it is about having a facility that looks like a pharmaceutical plant to any visiting inspector.
The way product moves through the building reflects that mindset. Raw material receipt and quarantine live in their own controlled area, distinct from primary processing. Extraction, formulation, filling, packaging, and finished-goods storage each occupy separate zones, with their own environmental controls and cleaning regimes designed to prevent cross‑contamination and mix‑ups. A dedicated in‑house lab supports in‑process controls and release testing, allowing SOMAÍ to qualify batches for multiple jurisdictions without relying entirely on third‑party labs.
Curaleaf International: seed‑to‑patient under one quality system
Curaleaf International shows what it looks like when a North American brand operates in the EU-GMP universe at scale. Through its Medalchemy site in Spain and a certified processing facility in Portugal, it manages import, manufacturing, and export of cannabis-based medicines into multiple regulated markets.
Those facilities are certified to make both commercial products and investigational batches, which forces tighter equipment qualification, auditable data capture, and full batch genealogy from raw material through final testing. Electronic batch records and quality systems tie together materials, process parameters, test results, and deviations for every lot.
Curaleaf’s European footprint is a live example of “seed‑to‑patient under GMP,” where cultivation, extraction, formulation, packaging, and distribution operate under a single quality framework rather than fragmented, state‑by‑state rules. It offers MSOs and vendors in North America a preview of the integration regulators will expect once cannabis is treated as medicine first and a consumer product second.
Panaxia: cannabis as an active pharmaceutical ingredient
Panaxia approaches the same challenge from the other direction: as a pharmaceutical company using cannabinoids as active ingredients. It was among the first Israeli cannabis manufacturers to achieve EU-GMP certification and later extended that standard to a facility in Malta, giving it a platform to supply EU markets like Germany.
Because Panaxia focuses on tablets, oils, and inhalable preparations rather than jars of flower, its facilities look and function like conventional drug plants. Production is broken into distinct areas for component preparation, product preparation, filling, and packaging; environmental controls and microbiological monitoring are designed around finished dosage forms. On top of that, the company maintains stability programs to support real shelf‑life and storage claims, as required for herbal medicinal products under EU expectations.
For engineers and QA staff, Panaxia underscores a simple point: once cannabis is treated as an API, the compliance target is not “a good grow” but a full pharmaceutical operation, with all the expectations that come with that label—climate-controlled storage, formal sampling plans, and ongoing stability studies included.
How EU-GMP reshapes the building itself
Across SOMAÍ, Curaleaf International, and Panaxia, several common design patterns are visible, and they are very different from most North American retrofits.
First, layout becomes a primary quality control tool. Facilities are carved into clean and dirty corridors, with airlocks and one‑way flows that prevent people, raw materials, and waste from crossing paths in uncontrolled ways. This is not just a matter of convenience; poorly designed traffic patterns are treated as real contamination and mix‑up risks.
Second, finishes and infrastructure are chosen for cleanability and predictability. EU-GMP guidance expects smooth, impervious walls and ceilings, with no cracks or cavities where dust, microbes, or residues can accumulate. Even floor drains, door frames, and viewing windows are specified to prevent backflow and make cleaning and inspection realistic. This is a long way from “painted drywall and epoxy” as a one-size-fits-all answer.
Third, HVAC is treated as a process parameter, not just comfort control. Pressure cascades and filtered air supply are used to keep dirtier areas from bleeding into cleaner ones, and defined cleanliness levels support different operations in different rooms. That type of system design and documentation will feel familiar to pharmaceutical engineers but is still unusual in most state‑licensed cannabis facilities.
The invisible layer: validation, software, and documentation
Underneath the visible infrastructure lies a layer of validation work and digital tooling that EU-GMP inspectors expect to see.
Critical equipment typically goes through a structured lifecycle that includes design qualification, factory and site acceptance testing, installation qualification, operational qualification, and performance qualification. Each stage generates documentation that shows the equipment is fit for purpose, installed correctly, and consistently delivers the expected performance.
To keep up with that level of scrutiny, EU-GMP operators rely heavily on validated software platforms. Electronic batch record systems, laboratory information management systems (LIMS), and quality management systems handle batch genealogy, test results, deviations, and corrective actions. Audit trails and access controls are configured so regulators can trust the data in front of them.
At the human level, good documentation practices and training become non‑negotiable. Staff must follow current SOPs, and the organization needs evidence that people are trained and that training is refreshed. For equipment and software vendors, this means that documentation, qualification support, and audit‑ready logs are part of the product, not optional extras.
QP expectations vs a state inspector’s checklist
The role of the Qualified Person is a useful lens for understanding the cultural gap. A QP personally signs off that each batch meets all regulatory and quality requirements before release. That decision is based on a review of manufacturing and packaging records, analytical results, deviations, and alignment with the product’s authorization.
By contrast, many US state inspections still revolve around security, diversion control, and inventory traceability—checking that cameras work, doors lock, tags match, and METRC (or similar) is up to date. A QP or EU inspector is far more likely to ask for validation reports, calibration logs, environmental monitoring trends, and root‑cause investigations from past issues.
For North American operators with ambitions beyond domestic adult‑use markets, moving closer to that level of scrutiny means investing in environmental monitoring programs, method validation, equipment qualification, structured change control, and formal stability studies. It also means choosing partners—consultants, equipment manufacturers, and software providers—who understand what “GMP‑ready” really entails.
Design and vendor takeaways
For MSO executives, facility designers, and technology vendors, the lesson from these EU-GMP plants is clear: if export or clinical channels are even a possibility, the cheapest time to think like a pharmaceutical manufacturer is before concrete is poured.
Here are a few practical takeaways:
- Treat EU-GMP (or an equivalent standard) as the design baseline if there is any plausible path to medical or international markets.
- Make QA/QC infrastructure—labs, LIMS, and QMS—as central as cultivation rooms and extraction trains, not afterthoughts.
- Choose equipment and software with qualification and validation in mind; documentation and audit trails will decide who gets into serious facilities.
- Engineer flows for people, materials, and waste with clean/dirty segregation in mind instead of simply filling an empty box with rooms.
- Build a documentation and training culture early, so the organization is ready when regulators show up and opportunities open beyond state borders.
EU-GMP cannabis facilities in Europe and Israel show where global cannabis manufacturing is already heading. For North American companies, they offer a concrete blueprint for how to design, equip, and document operations that can compete in a world where cannabis is treated as medicine, not just a regulated commodity.
